SEC Filing Summary: Xcyte Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xcyte Therapies, Inc. (Delaware corporation) on December 23, 2005, reporting events occurring on December 22, 2005. The registrant is headquartered in Seattle, Washington.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses corporate governance changes rather than financial performance.
Material Changes
Under Item 5.02(b), the company reported the departure of a director:
- Resignation: Jean Deleage resigned from the Board of Directors effective immediately on December 22, 2005.
- Committee Role: Mr. Deleage also served as a member of the Audit Committee.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed resignation.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors following Mr. Deleage's resignation.
- Verify the status of the Audit Committee to ensure it remains fully staffed and compliant with governance requirements.
- Check for any subsequent filings regarding the appointment of a replacement director.